UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 73

Sortiert nach

Activation of KRAS Mediates Resistance to Targeted Therapy in MET Exon 14-mutant Non-small Cell Lung Cancer

Clinical cancer research, 2019-02, Vol.25 (4), p.1248-1260

2019

Link zum Volltext

Verfügbarkeit prüfen

Changing the Therapeutic Landscape in Non-small Cell Lung Cancers: the Evolution of Comprehensive Molecular Profiling Improves Access to Therapy

Current Oncology Reports, 2017-04, Vol.19 (4), p.24-24, Article 24

2017

Link zum Volltext

Verfügbarkeit prüfen

Impact of Baseline Steroids on Efficacy of Programmed Cell Death-1 and Programmed Death-Ligand 1 Blockade in Patients With Non-Small-Cell Lung Cancer

Journal of clinical oncology, 2018-10, Vol.36 (28), p.2872-2878

2018

Link zum Volltext

Verfügbarkeit prüfen

Adagrasib in Non–Small-Cell Lung Cancer Harboring a KRASG12C Mutation

The New England journal of medicine, 2022-07, Vol.387 (2), p.120-131

2022

Link zum Volltext

Verfügbarkeit prüfen

First-in-Human Phase I/IB Dose-Finding Study of Adagrasib (MRTX849) in Patients With Advanced KRASG12C Solid Tumors (KRYSTAL-1)

Journal of clinical oncology, 2022-08, Vol.40 (23), p.2530-2538

2022

Link zum Volltext

Verfügbarkeit prüfen

Dynamic Management of Lung Cancer Care During Surging COVID-19

Frontiers in surgery, 2021-04, Vol.8, p.663364-663364

2021

Link zum Volltext

Verfügbarkeit prüfen

Seeing Beyond the Smoke: Reclassifying Lung Cancer by Smoking-Related Mutational Signatures

Journal of thoracic oncology, 2023-04, Vol.18 (4), p.396-398

2023

Link zum Volltext

Verfügbarkeit prüfen

Adagrasib in Non-Small-Cell Lung Cancer. Reply

The New England journal of medicine, 2022-09, Vol.387 (13), p.1238-1239

2022

Link zum Volltext

Verfügbarkeit prüfen

Activity of Adagrasib (MRTX849) in Brain Metastases: Preclinical Models and Clinical Data from Patients with KRASG12C-Mutant Non-Small Cell Lung Cancer

Clinical cancer research, 2022-08, Vol.28 (15), p.3318-3328

2022

Link zum Volltext

Verfügbarkeit prüfen

Next-generation sequencing based detection of germline and somatic alterations in a patient with four metachronous primary tumors

Gynecologic oncology reports, 2018-05, Vol.24, p.94-98

2018

Link zum Volltext

Verfügbarkeit prüfen

Amivantamab vs Mobocertinib in Exon 20 NSCLC

Oncology (Williston Park, N.Y.), 2023-08, Vol.37 (8), p.340

2023

Link zum Volltext

Verfügbarkeit prüfen

Presentation, Diagnosis and Management of Innominate Artery Thromboembolism

Journal of endovascular therapy, 2022-06, Vol.29 (3), p.451-456

2022

Link zum Volltext

Verfügbarkeit prüfen

Amivantamab plus lazertinib in osimertinib-relapsed EGFR-mutant advanced non-small cell lung cancer: a phase 1 trial

Nature medicine, 2023-10, Vol.29 (10), p.2577-2585

2023

Link zum Volltext

Verfügbarkeit prüfen

Stage IV lung carcinoids: spectrum and evolution of proliferation rate, focusing on variants with elevated proliferation indices

Modern pathology, 2019-08, Vol.32 (8), p.1106-1122

2019

Link zum Volltext

Verfügbarkeit prüfen

Afatinib in patients with metastatic or recurrent HER2-mutant lung cancers: a retrospective international multicentre study

European journal of cancer (1990), 2019-03, Vol.109, p.28-35

2019

Link zum Volltext

Verfügbarkeit prüfen

A Prospective Study of Circulating Tumor DNA to Guide Matched Targeted Therapy in Lung Cancers

JNCI : Journal of the National Cancer Institute, 2019-06, Vol.111 (6), p.575-583

2019

Link zum Volltext

Verfügbarkeit prüfen

Plain language summary of PAPILLON: amivantamab plus chemotherapy in untreated EGFR -mutated non-small-cell lung cancer

Future oncology (London, England), 2024-07, p.1-13

2024

Link zum Volltext

Verfügbarkeit prüfen

Defining a Space for NRG1 Fusion--Positive Tumors in Lung and GI Cancers

Oncology (Williston Park, N.Y.), 2024-01, Vol.38 (1), p.28

2024

Link zum Volltext

Verfügbarkeit prüfen

Multiple synchronous primary lung adenocarcinomas with distinct epidermal growth factor receptor mutations: A case report

Current problems in cancer. Case reports, 2022-09, Vol.7, p.100171, Article 100171

2022

Link zum Volltext

Verfügbarkeit prüfen

Selective Personalized RadioImmunotherapy for Locally Advanced Non-Small-Cell Lung Cancer Trial (SPRINT)

Journal of clinical oncology, 2024-02, Vol.42 (5), p.562

2024

Link zum Volltext

Verfügbarkeit prüfen

Adagrasib in Advanced Solid Tumors Harboring a KRAS G12C Mutation

Journal of clinical oncology, 2023-09, Vol.41 (25), p.4097

2023

Link zum Volltext

Verfügbarkeit prüfen

The Common Thread: A Case of Synchronous Lung Cancers and a Germline CHEK2 Mutation

Clinical lung cancer, 2022-01, Vol.23 (1), p.e1-e4

2022

Link zum Volltext

Verfügbarkeit prüfen

The incidence and predictors of new brain metastases in patients with non-small cell lung cancer following discontinuation of systemic therapy

Journal of neurosurgery, 2022-08, Vol.137 (2), p.544-554

2022

Link zum Volltext

Verfügbarkeit prüfen

Management of infusion-related reactions (IRRs) in patients receiving amivantamab in the CHRYSALIS study

Lung cancer (Amsterdam, Netherlands), 2023-04, Vol.178, p.166-171

2023

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 73

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(66)
Mit Volltextzugriff
(65)

Publikationsform

Artikel
(71)
Bücher
(1)
Berichte
(1)

Sprache

Englisch
(71)
Japanisch
(5)

Erscheinungsjahr

n.n

Thema

Life Sciences & Biomedicine
(31)
Science & Technology
(31)
Oncology
(23)
Humans
(21)
Carcinoma, Non-Small-Cell Lung - Drug Therapy
(13)
Lung Neoplasms - Genetics
(13)
Mutation
(12)
Carcinoma, Non-Small-Cell Lung - Genetics
(11)
Lung Cancer
(10)
Lung Neoplasms - Drug Therapy
(10)
Aged
(9)
Female
(9)
Middle Aged
(8)
Proto-Oncogene Proteins P21 - Genetics
(8)
Male
(7)
Adult
(6)
Next-Generation Sequencing
(6)
Non-Small Cell Lung Cancer
(6)
Patients
(6)
Tumors
(6)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Activation of KRAS Mediates Resistance to Targeted Therapy in MET Exon 14-mutant Non-small Cell Lung Cancer

Changing the Therapeutic Landscape in Non-small Cell Lung Cancers: the Evolution of Comprehensive Molecular Profiling Improves Access to Therapy

Impact of Baseline Steroids on Efficacy of Programmed Cell Death-1 and Programmed Death-Ligand 1 Blockade in Patients With Non-Small-Cell Lung Cancer

Adagrasib in Non–Small-Cell Lung Cancer Harboring a KRASG12C Mutation

Amivantamab in EGFR Exon 20 Insertion-Mutated Non-Small-Cell Lung Cancer Progressing on Platinum Chemotherapy: Initial Results From the CHRYSALIS Phase I Study

First-in-Human Phase I/IB Dose-Finding Study of Adagrasib (MRTX849) in Patients With Advanced KRASG12C Solid Tumors (KRYSTAL-1)

Dynamic Management of Lung Cancer Care During Surging COVID-19

Seeing Beyond the Smoke: Reclassifying Lung Cancer by Smoking-Related Mutational Signatures

Adagrasib in Non-Small-Cell Lung Cancer. Reply

Activity of Adagrasib (MRTX849) in Brain Metastases: Preclinical Models and Clinical Data from Patients with KRASG12C-Mutant Non-Small Cell Lung Cancer

Next-generation sequencing based detection of germline and somatic alterations in a patient with four metachronous primary tumors

Amivantamab vs Mobocertinib in Exon 20 NSCLC

Presentation, Diagnosis and Management of Innominate Artery Thromboembolism

Amivantamab plus lazertinib in osimertinib-relapsed EGFR-mutant advanced non-small cell lung cancer: a phase 1 trial

Stage IV lung carcinoids: spectrum and evolution of proliferation rate, focusing on variants with elevated proliferation indices

Afatinib in patients with metastatic or recurrent HER2-mutant lung cancers: a retrospective international multicentre study

A Prospective Study of Circulating Tumor DNA to Guide Matched Targeted Therapy in Lung Cancers

Plain language summary of PAPILLON: amivantamab plus chemotherapy in untreated EGFR -mutated non-small-cell lung cancer

Defining a Space for NRG1 Fusion--Positive Tumors in Lung and GI Cancers

Multiple synchronous primary lung adenocarcinomas with distinct epidermal growth factor receptor mutations: A case report

Selective Personalized RadioImmunotherapy for Locally Advanced Non-Small-Cell Lung Cancer Trial (SPRINT)

Adagrasib in Advanced Solid Tumors Harboring a KRAS G12C Mutation

The Common Thread: A Case of Synchronous Lung Cancers and a Germline CHEK2 Mutation

The incidence and predictors of new brain metastases in patients with non-small cell lung cancer following discontinuation of systemic therapy

Management of infusion-related reactions (IRRs) in patients receiving amivantamab in the CHRYSALIS study

Suchergebnisse filtern